First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

July 29, 2014

Primary Completion Date

July 31, 2018

Study Completion Date

August 28, 2018

Conditions
Advanced Stage Solid Tumors
Interventions
DRUG

TEW-7197

Single daily doses by oral administration on Days 1, 2, 3, 4, 5, Days 8, 9, 10, 11, 12, Days 15, 16, 17, 18, 19 and Days 22, 23, 24, 25, 26 of each 28 day cycle. Starting dose is 30 mg, with escalation to 60 mg, and subsequent dose escalation using a modified Fibonacci algorithm.

Trial Locations (3)

27710

Durham

37203

Nashville

37232

Nashville

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National OncoVenture

OTHER

lead

MedPacto, Inc.

INDUSTRY

NCT02160106 - First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors | Biotech Hunter | Biotech Hunter